Academic researchers in Massachusetts believe the standard BCG (bacillus Calmette-Guérin) vaccine could have a remarkable second use: a treatment to reverse advanced type 1 diabetes.
US biotech vTv Therapeutics was showcasing mid-stage trial results from its oral small molecule GLP-1 pill at this year's American Diabetes Association conference, as it searches for partne
While a beta cell replacement therapy is the dream of all type 1 patients, new medical devices are hitting the market, and promise more peace of mind. However US patients could find access to t
The rate of innovation in devices for type 1 diabetes patients has accelerated rapidly in recent years, with digital technology and medical devices converging to offer new control.
The CANVAS trial was supposed to provide definitive cardiovascular safety data for Janssen’s Invokana (canagliflozin) in type 2 diabetes – and while it has succeeded in this regard, investi
The US FDA announced today that it has cleared two novel gene therapies for sickle cell disease: Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia.
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio